B Cell News and Research

RSS

Prognosis still poor for EVB in cirrhosis

The current standard of care for esophageal variceal bleeding in liver cirrhosis is very effective at controlling bleeding but patient prognosis remains poor, say the authors of an Italian study.

1 Oct 2012

Multiple Epo doses with hypothermia offers neonate neuroprotection

Multiple doses of erythropoietin in combination with hypothermia could be neuroprotective in neonates with hypoxic‑ischemic encephalopathy, say researchers.

1 Oct 2012

New treatment target brings hope for scleroderma patients

Research presented at the European Academy of Dermatology and Venereology in Prague, Czech Republic, suggests that inhibition of the SMAD protein may be a viable therapeutic target in scleroderma patients.

1 Oct 2012

WBC counts in diabetes risk prediction

An elevated white blood cell count in young men is an independent predictor for the development of diabetes in later life, suggest study findings.

1 Oct 2012

Clinical need, effectiveness, fairness should drive drugs allocation

A policy that is transparent, fair to patients and healthcare providers, and is based on clinical need is an ethically justifiable approach to rationing drugs that are in critically short supply, report researchers.

1 Oct 2012

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

AVEO Oncology today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company's HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung cancer (NSCLC) were presented at the 2012 Congress of the European Society for Medical Oncology (ESMO).

1 Oct 2012

Medistem initiates collaboration with Superview Biotechnology

Medistem Inc announced today the initiation of a collaboration with Superview Biotechnology Co. Ltd, a subsidiary of Yinhuan Holding Co from Yixing, China.

1 Oct 2012

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and Seattle Genetics, Inc., today announced preliminary data from one arm of a three arm phase I, open-label, multicenter study designed to determine the safety and activity of sequential and combination treatment approaches of brentuximab vedotin with CHOP or CH-P chemotherapy in newly diagnosed patients with CD30-positive mature T- and NK- cell lymphomas.

1 Oct 2012

Inhibiting DUSP6 protein can restore immune cells’ responsiveness to a more youthful state

The older we get, the weaker our immune systems tend to become, leaving us vulnerable to infectious diseases and cancer and eroding our ability to benefit from vaccination. Now Stanford University School of Medicine scientists have found that blocking the action of a single protein whose levels in our immune cells creep steadily upward with age can restore those cells' response to a vaccine.

1 Oct 2012

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Exelixis, Inc. today announced interim data from 51 patients with metastatic castration-resistant prostate cancer (CRPC) and bone metastases receiving a 40 mg daily dose of cabozantinib in an ongoing non-randomized expansion (NRE) cohort of a phase 2 randomized discontinuation trial.

1 Oct 2012

Researchers identify how p110delta molecule controls the body's inflammatory responses

Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism.

1 Oct 2012

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma.

1 Oct 2012

Common RNA pathway links frontotemporal lobar dementia with ALS

Two proteins previously found to contribute to ALS, also known as Lou Gehrig's disease, have divergent roles. But a new study, led by researchers at the Department of Cellular and Molecular Medicine at the University of California, San Diego School of Medicine, shows that a common pathway links them.

1 Oct 2012

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

Exelixis, Inc. today reported preliminary data from an ongoing phase 1 dose escalation study of cabozantinib in Japan.

1 Oct 2012

CIB2 genetic mutation responsible for deafness associated with Usher syndrome type 1

Researchers at the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center have found a new genetic mutation responsible for deafness and hearing loss associated with Usher syndrome type 1.

1 Oct 2012

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.

1 Oct 2012

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

1 Oct 2012

Study finds differences and similarities between iPSCs and cancer cells

UC Davis investigators have found new evidence that a promising type of stem cell now being considered for a variety of disease therapies is very similar to the type of cells that give rise to cancer. The findings suggest that although the cells -- known as induced pluripotent stem cells (iPSCs) -- show substantial promise as a source of replacement cells and tissues to treat injuries, disease and chronic conditions, scientists and physicians must move cautiously with any clinical use because iPSCs could also cause malignant cancer.

29 Sep 2012

Sorafenib does not improve overall survival among patients with NSCLC

Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. However, a post-hoc biomarker analysis of the trial data that was also presented suggests that patients with EGFR-mutant tumors may benefit.

29 Sep 2012

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

ARIAD Pharmaceuticals, Inc. today announced the initial clinical results on its investigational, tyrosine-kinase inhibitor, AP26113, in patients with advanced non-small cell lung cancer (NSCLC) from an ongoing Phase 1/2 trial.

29 Sep 2012

B Cell News and Research

Prognosis still poor for EVB in cirrhosis

Multiple Epo doses with hypothermia offers neonate neuroprotection

New treatment target brings hope for scleroderma patients

WBC counts in diabetes risk prediction

Clinical need, effectiveness, fairness should drive drugs allocation

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

Medistem initiates collaboration with Superview Biotechnology

Takeda, Seattle Genetics announce preliminary data from brentuximab vedotin phase I study on sALCL

Inhibiting DUSP6 protein can restore immune cells’ responsiveness to a more youthful state

Exelixis announces interim data from cabozantinib phase 2 trial on metastatic CRPC

Researchers identify how p110delta molecule controls the body's inflammatory responses

Combination of dabrafenib and trametinib delays development of treatment resistance in MM patients

Common RNA pathway links frontotemporal lobar dementia with ALS

Exelix reports preliminary data from cabozantinib phase 1 study on solid tumors

CIB2 genetic mutation responsible for deafness associated with Usher syndrome type 1

New trial results on pazopanib and temsirolimus have important implications for patients with RCC

Lilly announces new data from two Phase II ramucirumab trials on NSCLC

Study finds differences and similarities between iPSCs and cancer cells

Sorafenib does not improve overall survival among patients with NSCLC

ARIAD announces initial results from AP26113 Phase 1/2 trial on non-small cell lung cancer

Using single B cell screening to boost antibody discovery eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News